Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support and helps correct hypoglycemia. Sodium chloride is an electrolyte that maintains osmotic balance and fluid volume.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement,Treatment of dehydration,Caloric supplementation in parenteral nutrition
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; dosage depends on fluid and electrolyte requirements. Typical maintenance: 75-150 m L/kg/day for adults, administered as continuous infusion.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable for dextrose as it is rapidly metabolized; plasma glucose half-life is approximately 1.7-2.0 hours after IV infusion but highly variable depending on metabolic demand and insulin activity. For sodium chloride, ions are continuously regulated by renal handling; no traditional half-life.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the citric acid cycle. Sodium chloride is not metabolized; it is excreted renally.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle; negligible renal excretion (<5%). Sodium chloride is excreted renally with sodium and chloride ions freely filtered and variably reabsorbed (99% reabsorption under normal conditions, but excretion increases with excess intake).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: negligible (<1%); not protein-bound. Sodium and chloride ions: negligible (<1%); are free ions in plasma.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: approximately 0.25-0.4 L/kg, reflecting distribution primarily into extracellular fluid and cells. Sodium chloride: sodium distributes mainly in extracellular fluid (Vd ~0.2 L/kg for sodium), chloride follows sodium distribution.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% (complete bioavailability). No other relevant routes; oral dextrose is absorbed but formulation is for IV use only.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR >= 50 m L/min: no adjustment; GFR 30-49 m L/min: reduce total volume by 20-30% or use with caution; GFR <30 m L/min: avoid use due to risk of fluid overload and hypernatremia unless carefully monitored.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh A: no adjustment; Child-Pugh B: monitor for fluid overload and electrolyte disturbances; Child-Pugh C: use with caution, reduce infusion rate and volume, may need diuretic therapy.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion: neonates: 60-120 m L/kg/day; infants: 100-120 m L/kg/day; children: 75-100 m L/kg/day; adjust based on clinical status and serum electrolytes.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients may require reduced total volume and slower infusion rate due to decreased renal function and increased risk of fluid overload; monitor serum sodium, potassium, and fluid balance closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperglycemia in patients with diabetes mellitus,Risk of fluid overload in patients with heart failure or renal impairment,Electrolyte imbalances with prolonged use,Do not administer if solution contains particulate matter or is discolored
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia,Hypernatremia,Fluid overload,Known hypersensitivity to any component
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No food interactions. May affect glucose control in diabetics; maintain consistent carbohydrate intake.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk has been identified at standard infusion rates. First trimester: No known risk. Second trimester: No known risk. Third trimester: Use caution to avoid fluid/electrolyte imbalance, which may affect fetal homeostasis.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Both dextrose and sodium chloride are normal constituents of breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio: Not applicable (endogenous substances). Compatible with breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering electrolyte and glucose homeostasis. No standard dose adjustment required for maintenance fluids; however, infusion rate should be tailored to maternal volume status, serum sodium, and glucose levels. Monitor for hyperglycemia in gestational diabetes.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Used for maintenance fluid therapy; monitor for fluid overload in patients with CHF or renal impairment. Check serum glucose in diabetics as dextrose may cause hyperglycemia. Avoid in resuscitation due to hypotonicity.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any swelling of hands, feet, or shortness of breath immediately.,If diabetic, monitor blood glucose closely.,This solution provides hydration and electrolytes; do not adjust infusion rate yourself.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support and helps correct hypoglycemia. Sodium chloride is an electrolyte that maintains osmotic balance and fluid volume.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Intravenous infusion; dosage depends on fluid and electrolyte requirements. Typical maintenance: 75-150 m L/kg/day for adults, administered as continuous infusion.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk has been identified at standard infusion rates. First trimester: No known risk. Second trimester: No kn. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.